VANCOUVER, British Columbia - Helix BioPharma Corp. (TSX: HBP, OTC PINK: HBPCD, FRANKFURT: HBP0), a clinical-stage oncology company, has announced immediate changes to its Board of Directors. Janusz Grabski has resigned from the board, and Thomas Mehrling, M.D., Ph.D., the company's Chief Executive Officer, has been appointed as a director, effective immediately.
The appointment of Dr. Mehrling is made pursuant to a board nomination right granted to Laevoroc Immunology AG in connection with Helix's 2025 acquisition of substantially all of the assets of Laevoroc Immunology AG and Laevoroc Chemotherapy AG. This strategic acquisition, as detailed in a company release, brought in pre-IND candidates LEUMUNA™ and GEMCEDA™, which are now part of Helix's pipeline (https://www.helixbiopharma.com/fy2025/helix-biopharma-secures-pre-ind-candidates-leumuna-and-gemceda-in-strategic-acquisition-from-the-laevoroc-group/).
These changes are intended to ensure that the board continues to meet Helix's evolving governance and capital markets requirements and has the composition and experience needed to support the company's clinical development and broader corporate objectives. The board expressed gratitude to Mr. Grabski for his service and contributions, wishing him success in his future endeavors.
The significance of this board restructuring lies in its alignment with Helix's strategic direction. By adding the CEO to the board, the company strengthens the link between management and governance, potentially streamlining decision-making processes. This is particularly crucial as Helix advances its lead candidate, L-DOS47, a clinical-stage antibody-enzyme conjugate for non-small cell lung cancer (NSCLC), and prepares its other pipeline candidates for regulatory milestones.
The board's composition now reflects a more integrated leadership approach, which may enhance investor confidence and support the company's capital markets activities. With a focus on difficult-to-treat cancers, Helix is positioning itself to meet the needs of underserved patient populations. The appointment of Dr. Mehrling, who has been leading the company's strategic initiatives, signals a commitment to cohesive execution of its clinical and corporate plans.
As Helix continues to develop its pipeline, including LEUMUNA™ for post-transplant leukemia relapse and GEMCEDA™ for advanced solid tumors, these governance changes are timely. The company's shares are listed on the Toronto Stock Exchange, quoted on the OTC Pink Market, and listed on the Frankfurt Stock Exchange, and such board adjustments are often viewed as steps to maintain robust corporate governance standards.
For more information about Helix BioPharma and its pipeline, visit the company's website at https://www.helixbiopharma.com/.
